Current clinical trials and research opportunities can be found on their website. See also
List of cutaneous conditions
TGM3
PADI3
Trichohyalin

References
External links

Uncombable hair syndrome at NIHs Office of Rare Diseases
Estradiol/drospirenone (E2/DRSP), sold under the brand name Angeliq, is a combination of estradiol (E2), an estrogen, and drospirenone (DRSP), a progestin, antimineralocorticoid, and antiandrogen, which is used in menopausal hormone therapy, specifically the treatment of menopausal syndrome and osteoporosis, in postmenopausal women. It is taken by mouth and contains 0.5 to 1 mg E2 and 0.25 to 0.5 mg DRSP per tablet. The medication was approved in the United States in 2005. It is marketed widely throughout the world. See also
Estetrol/drospirenone
Ethinylestradiol/drospirenone
Ethinylestradiol/drospirenone/levomefolic acid
Ethinylestradiol/drospirenone/prasterone
List of combined sex-hormonal preparations § Estrogens and progestogens

References
External links
Angeliq (estradiol/drospirenone) FDA Label
Estradiol/drospirenone (Angeliq) - AdisInsight